Aradigm Corporation (OTCBB:ARDM) announced it has initiated a Phase 2 study of its proprietary inhaled liposomal formulation of ciprofloxacin in patients with cystic fibrosis. This safety and efficacy study follows the successful completion of a Phase 1 safety, tolerability and pharmacokinetics trial in healthy volunteers and the previously executed preclinical toxicology program. [click link for full article]

More: continued here

This entry was posted on Sunday, December 2nd, 2007 at 5:12 am and is filed under Cystic Fibrosis. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.